Replimune Group, Inc. — Form 10-K summary
Reporting period: Fiscal year ended March 31, 2020, with comparative financial information for fiscal 2019 and 2018. The filing also reports unaudited results for the quarter ended March 31, 2020. Although the request metadata says “2019 Q4,” the filing is the FY2020 Form 10-K; its Q4 figures are for 2020.
Business context
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies using its Immulytic HSV-1 platform. It has no approved products and has not generated product-sales revenue. RP1 is its lead candidate; RP2 is in Phase 1 development and RP3 remains preclinical.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $38.8 million | $22.2 million |
| General and administrative expense | $17.4 million | $8.8 million |
| Total operating expenses | $56.2 million | $30.9 million |
| Net loss | $52.6 million | $30.8 million |
| Basic and diluted net loss per share | $1.54 | $1.33 |
| Net cash used in operating activities | $60.6 million | $25.4 million |
| Cash, cash equivalents and short-term investments at year-end | $168.6 million | $134.8 million |
| Working capital at year-end | $162.4 million | $131.1 million |
| Long-term debt, net of discount, at year-end | $9.8 million | None reported |
Margins are not meaningful given the absence of product revenue. FY2020 financing cash flow was $100.2 million, mainly from the follow-on equity and pre-funded warrant offering, ATM sales and $10.0 million of debt proceeds. Total liabilities were $50.4 million, including $32.0 million of recognized lease liabilities. Accumulated deficit was $112.3 million.
For the quarter ended March 31, 2020, operating expenses were $16.4 million and net loss was $15.8 million, or $0.41 per share.
Changes versus prior period
- Net loss increased by $21.8 million year over year as operating expenses rose $25.3 million. R&D expense increased $16.6 million, reflecting higher RP1 trial costs, staffing and manufacturing-facility costs; G&A expense rose $8.7 million as the company expanded operations.
- Operating cash use increased $35.2 million to $60.6 million. Cash and short-term investments nevertheless increased, supported by financing proceeds.
- FY2020 other income included $3.1 million of UK R&D incentives and $2.4 million of investment income. The prior-year $5.5 million warrant-liability fair-value charge did not recur.
- The company adopted lease accounting guidance in FY2020, recognizing right-of-use assets and lease liabilities; this affected reported balance-sheet and cash-flow items.
Outlook, commentary and risks
- Management estimated existing cash, cash equivalents and short-term investments would fund planned operating expenses and capital needs through 2022. The financial statements state resources were expected to last at least 12 months from issuance. Both estimates depend on assumptions; additional financing may be required.
- RP1 development includes a randomized Phase 2 trial in approximately 240 CSCC patients with cemiplimab, with a primary readout expected in 2022. BMS supplies nivolumab at no cost for specified RP1 and RP2 trials; Regeneron shares half the costs of the RP1/cemiplimab trial.
- Management expected initial RP2 Phase 1 data in the second half of 2020 and planned to seek clearance to begin RP3 clinical development during 2020. These are forward-looking plans, not outcomes reported in this filing.
- COVID-19 was delaying or expected to delay enrollment and treatment in some trials, with the extent and duration uncertain. The company anticipated delayed accrual of the non-melanoma skin cancer cohort into late 2020 and MSI-H/dMMR development decisions into 2021. It also planned to replace a bladder-cancer cohort with anti-PD-1-refractory NSCLC.
- Small early clinical cohorts showed encouraging activity, including reported responses in melanoma and CSCC; these preliminary findings do not establish efficacy or approval prospects. The filing describes RP1 as investigational and all candidates as subject to clinical and regulatory risk.
- Material weaknesses remained in internal controls over financial reporting, and management concluded disclosure controls were not effective as of March 31, 2020. The weaknesses involved insufficient accounting staffing and controls for complex transactions. Management reported remediation efforts underway; the auditor did not audit internal controls. The financial-statement audit opinion was unqualified.
- Other key risks include continued losses and financing needs, clinical-trial and regulatory uncertainty, manufacturing scale-up and facility execution, reliance on third-party suppliers and collaborators, competition, intellectual-property protection, and reimbursement and pricing uncertainty. No material legal proceedings were reported.
- After year-end, on June 1, 2020, the Hercules facility was amended from $30 million to $40 million, subject to terms and milestones. At March 31, $10 million was drawn; the filing describes the additional borrowing capacity as available in later advances.
Investor verification points
- Verify the latest cash balance, quarterly cash burn and whether management’s stated runway remains current.
- Review trial enrollment, COVID-related delays, protocol changes and updated data for RP1, RP2 and RP3; distinguish preliminary response counts from mature controlled results.
- Check Hercules loan availability, milestone conditions, interest terms, collateral and repayment obligations, alongside lease commitments.
- Assess dilution from outstanding options, pre-funded warrants and potential ATM or other equity issuance; the company reported 36.8 million common shares outstanding as of May 29, 2020.
- Track remediation and testing of the disclosed material weaknesses and whether management later concludes controls are effective.